Boehringer Ingelheim announced that Japan has approved JASCAYD® (nerandomilast) for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
It is the first medicine of its kind (PDE4B inhibitor) that helps both the immune system and scarring in the lungs. Japan is the fourth country in the world to approve it, giving patients a new treatment option for these serious lung diseases.
The approval is based on large Phase III studies called FIBRONEER™-IPF and FIBRONEER™-ILD. In these studies, JASCAYD® slowed lung damage compared to a placebo. When both studies were combined, patients taking JASCAYD® had a 59% lower risk of death compared to those not receiving the medicine.
In Japan, about 10,000–30,000 people have IPF. There are no national numbers for PPF yet. Current treatments exist, but many patients either do not start or stop early because of side effects. JASCAYD® offers a new option for these patients.
As per Coherent Market Insights, the Pharmaceutical Market will grow at a 8.3% compound annual growth rate (CAGR) from 2026 to 2033, from USD 1.96 Tn in 2026 to around USD 3.43 Tn by 2033. This significant growth trajectory is driven by the rising healthcare demands, advancements in drug development, and increasing investments in biopharmaceutical research worldwide, positioning the market for robust expansion over the forecast period.
"Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis are rare and intractable diseases, which have limited treatment options. Specifically, in IPF, we have seen little clinical trial success over the past decade,” said Professor Arata Azuma, MD, PhD, Head of the Department of Respiratory Medicine, Tokorozawa Mihara General Hospital/Emeritus Professor, Nippon Medical School. “The approval of JASCAYD® is a major achievement that has the potential to transform the treatment paradigm for these conditions. With a novel mechanism of action that exerts both antifibrotic and anti-inflammatory effects in the lungs, JASCAYD® demonstrated a reduction in lung function decline in both FIBRONEER™-IPF and FIBRONEER™-ILD. Furthermore, a pooled analysis of these trials demonstrated a nominally significant reduction in risk of death. The introduction of JASCAYD® as a new treatment option offers great hope to people living with IPF and PPF.”
“Today’s approval of JASCAYD® in Japan marks a pivotal moment for people living with IPF and PPF and, in IPF, the first new treatment option in more than a decade,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “With JASCAYD®, physicians in Japan now have a new oral treatment option that combines clinically meaningful efficacy with a well-tolerated profile that can support sustained treatment, helping more patients stay on therapy and face the future with greater confidence.”
Source:
News: Boehringer Ingelheim
